Business context and reporting period
This is Diffusion Pharmaceuticals Inc.’s unaudited Form 10-Q for the quarter and nine months ended September 30, 2018. The request metadata names Cervomed Inc., but the filing identifies Diffusion Pharmaceuticals Inc. as the registrant. Diffusion is a clinical-stage biotechnology company developing trans sodium crocetinate (TSC), primarily to improve radiation and chemotherapy effectiveness in hypoxic tumors. It has no product revenue.
Financial performance and position
- Revenue: None; the company does not expect product-sale revenue for the foreseeable future.
- Q3 results: Operating expenses were $7.0 million, including a $4.2 million noncash goodwill impairment. Net loss was $6.7 million, or $0.13 per share, versus net income of $5.1 million, or $0.21 per share, in Q3 2017. The prior-year profit included an $8.4 million gain from remeasuring warrant liabilities.
- Nine-month results: Operating expenses were $13.4 million and net loss was $12.8 million, or $0.44 per share, compared with a $3.2 million net loss, or $0.35 per share, in the prior-year period. The 2018 loss included the goodwill impairment; 2017 results included substantial warrant-related gains and expenses and financing costs.
- Expense trends: Q3 R&D fell to $1.2 million from $1.8 million, primarily due to lower Phase 3 trial start-up and manufacturing costs. Nine-month R&D rose to $4.4 million from $3.9 million, mainly reflecting higher Phase 3 GBM trial costs. Nine-month G&A decreased to $4.7 million from $4.9 million.
- Cash and liquidity: Cash and equivalents were $11.0 million at September 30, 2018, versus $8.9 million at December 31, 2017; working capital was $10.6 million. Operating cash use for the first nine months was $7.7 million, compared with $10.1 million in 2017. Financing provided $9.9 million, principally from the January common-stock-and-warrant offering. Investing cash flow was zero.
- Debt and balance sheet: No debt was outstanding at quarter-end; the company repaid approximately $0.6 million of convertible debt principal and interest in Q2. Total liabilities were $2.7 million and total assets $23.6 million. Goodwill declined to $2.7 million after the impairment; the $8.6 million RES-529 intangible asset was not impaired.
- Margins: Not meaningful to report because the company had no revenue.
Material changes and notable items
- The January 2018 offering raised approximately $10.8 million net and included 15 million common shares and warrants; outstanding Series A preferred stock converted into common stock, including shares issued for accrued dividends and a make-whole feature. Common shares outstanding were 50.6 million at September 30, compared with 14.5 million at December 31, 2017.
- Management recorded a $4.2 million noncash goodwill impairment after the company’s market capitalization remained below the carrying value of equity during Q3. No impairment was recorded on RES-529.
- The 2017 comparison periods included large, nonrecurring warrant valuation and financing items, so reported earnings comparisons are affected by financing and accounting changes as well as operating expenses.
- The company recognized income-tax benefits of $0.2 million in Q3 and $0.5 million for the nine months, related to the 2017 Tax Act.
Outlook, risks and contingencies
- Management estimated that September 30 cash would fund operations into September 2019, but stated that additional funding would be needed to complete the Phase 3 TSC trial and pursue planned development. The filing reports substantial doubt about the company’s ability to continue as a going concern because it has no revenue, recurring losses and depends on raising capital.
- The Phase 3 INTACT trial in newly diagnosed inoperable glioblastoma was enrolling; the planned total enrollment is 236. The initial eight patients were assigned TSC dose escalation alongside temozolomide, subject to safety review. The company also reported FDA authorization to enroll patients in the PHAST-TSC Phase 2 acute-stroke trial; timing depended on contract negotiations and additional funding.
- The company is exploring options for RES-529, including possible out-licensing. No quantified earnings or revenue guidance was provided.
- Nasdaq granted an extension through February 25, 2019 to regain compliance with its $1.00 minimum bid-price rule. A reverse split had been authorized by stockholders, with the ratio and timing left to the board.
- A former CEO’s claims were in arbitration, with a dismissal hearing scheduled for November 19, 2018. The company disputed the claims; it could not estimate the outcome or any potential loss.
- The filing identifies clinical-trial, regulatory, financing, intellectual-property, personnel, third-party performance and Nasdaq-listing risks. Management said disclosure controls were effective and there were no material changes in internal control during the quarter.
Important facts for investors to verify
- Confirm the issuer identity: the source filing is for Diffusion Pharmaceuticals Inc., not Cervomed Inc.
- Review cash burn, funding runway, and whether additional financing or partnerships are secured; management’s runway estimate was into September 2019.
- Track INTACT enrollment, trial progress and safety review, as well as PHAST-TSC launch timing and funding.
- Check Nasdaq bid-price compliance progress and any board action on the authorized reverse split.
- Assess the potential dilution from outstanding warrants (31.3 million) and stock options (3.2 million), and monitor the unresolved former-CEO dispute.